SCHEMBL204707

SCHEMBL204707

O=C(Cl)c1ccc(-c2ccccn2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A7 Q99884 1/20 0.52
TRPV1 Q8NER1 2/20 0.51
ABL1 P00519 1/20 0.50
BCR P11274 1/20 0.50
CHEK2 O96017 2/20 0.48
DHODH Q02127 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
P4HTM Q9NXG6 2/20 0.47
CYP2A6 P11509 1/20 0.47
KDM4E B2RXH2 2/20 0.46
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
CCR1 P32246 1/20 0.46
CCR5 P51681 1/20 0.46
CCR8 P51685 1/20 0.46
METAP1 P53582 1/20 0.46
BLM P54132 1/20 0.46
HIF1A Q16665 1/20 0.46
DOHH Q9BU89 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688109 1.00 SLC6A7 (0.52) SLC6A7TRPV1ABL1BCRCHEK2
Hydrochloric Acid SCHEMBL6717689 0.98 SLC6A7 (0.51) SLC6A7TRPV1ABL1BCRCHEK2
SCHEMBL27605053 0.85 SLC6A7 (0.55) SLC6A7TRPV1ABL1BCRDHODH
SCHEMBL207571 0.84 CNR1 (0.54) CHEK2DHODHL3MBTL1P4HTMCYP2A6
SCHEMBL2459153 0.83 SLC6A7 (0.54) SLC6A7TRPV1ABL1BCRCHEK2
SCHEMBL5858 0.83 KDM4E (0.61) SLC6A7TRPV1DHODHKDM4EKDM6B
SCHEMBL13326879 0.83 KMT2A (0.58) SLC6A7TRPV1ABL1BCRDHODH
SCHEMBL29788328 0.83 KDM4E (0.61) SLC6A7TRPV1DHODHKDM4EKDM6B
SCHEMBL18573104 0.82 CHEK2 (0.47) SLC6A7TRPV1ABL1BCRCHEK2
SCHEMBL28214265 0.82 CYP2A6 (0.57) SLC6A7DHODHL3MBTL1P4HTMCYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479873-B2 Metal complexes UDC Ireland (IE) 2025-11-25 US disclosed
EP-4559902-A2 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2025-05-28 EP disclosed
EP-3256218-B1 A KDM1A INHIBITOR AND ITS USE IN THERAPY IMAGO BIOSCIENCES INC (US) 2024-12-11 EP disclosed
US-20230322826-A1 METAL COMPLEXES UDC IRELAND LIMITED (IE) 2023-10-12 US disclosed
US-20230322826-A1 METAL COMPLEXES UDC IRELAND LIMITED (IE) 2023-10-12 US disclosed
US-11773068-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-10-03 US disclosed
US-11773068-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-10-03 US disclosed
US-11713332-B2 Metal complexes MERCK PATENT GMBH (DE) 2023-08-01 US disclosed
US-11713332-B2 Metal complexes MERCK PATENT GMBH (DE) 2023-08-01 US disclosed
US-11713332-B2 Metal complexes MERCK PATENT GMBH (DE) 2023-08-01 US disclosed
US-6323227-B1 PRODRUGS AVENTIS PHARMACEUTICALS PRODUCTS INC. 2001-11-27 US disclosed
EP-1102535-A2 COMPOUNDS AND METHODS SmithKline Beecham Corporation (US) 2001-05-30 EP disclosed
US-6140504-A Substituted intermediate compounds for the preparation of n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-10-31 US disclosed
US-6080767-A Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-06-27 US disclosed
EP-0906094-A4 SUBSTITUTED N- (AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES RHONE POULENC RORER PHARMA (US) 2000-05-17 EP disclosed
WO-2000006085-A2 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2000-02-10 WO disclosed
EP-0931060-A1 SUBSTITUTED N- (AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1999-07-28 EP disclosed
EP-0906094-A1 SUBSTITUTED N- (AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1999-04-07 EP disclosed
WO-1999000356-A1 SUBSTITUTED N-[(AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) 1999-01-07 WO disclosed
WO-1997024118-A1 SUBSTITUTED N-[(AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479873-B2 Metal complexes AP1M1, SOD1, AP3M1 SLC6A7 3841/4885TRPV1 1420/4885ABL1 2641/4885
US-11713332-B2 Metal complexes AP1M1, SOD1, AP3M1 SLC6A7 3841/4885TRPV1 1420/4885ABL1 2641/4885
US-20230322826-A1 METAL COMPLEXES AP1M1, SOD1, AP3M1 SLC6A7 3841/4885TRPV1 1420/4885ABL1 2641/4885
US-11773068-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A SLC6A7 4257/4885TRPV1 4863/4885ABL1 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.